10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Shares of Futura Medical moved higher yesterday, as it announced that it has entered into a licensing agreement with m8 Pharmaceuticals, a specialty biopharmaceutical company focused on commercialization in Latin America, for the rights to exclusively develop and commercialize the company's topical, gel-based erectile dysfunction (ED) treatment MED3000, in Brazil and Mexico. 1 September 2021
Dutch drugmaker Centrient Pharmaceuticals, an antibiotics manufacturer wholly-owned by Bain Capital, has acquired Vadodara, India-based Astral SteriTech, a manufacturer in sterile antibiotic injectable finished dosage forms. 1 September 2021
Teva Pharmaceutical Industries and its partner MedinCell have announced that the New Drug Application (NDA) for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for schizophrenia has been accepted by the US Food and Drug Administration (FDA). 1 September 2021
Japanese pharma major Astellas Pharma has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy (XLMTM). 1 September 2021
Swiss pharma giant Novartis has reached a commercial agreement with the National Health Service (NHS) in England as part of a collaboration to pioneer a first-of-its-kind population health management approach to address elevated "bad" low-density lipoprotein (LDL)-cholesterol in eligible patients with atherosclerotic cardiovascular disease (ASCVD) across England. 1 September 2021
The US Centers for Disease Control and Prevention (CDC) has officially endorsed the recommendation for use of tozinameran, the coronavirus vaccine produced by Pfizer and BioNTech. 31 August 2021
Johnson & Johnson’s pharmaceutical arm, Janssen, has announced results from a post-hoc pooled analysis of the Phase III GRIPHON and Phase IIIb TRITON studies. 31 August 2021
Shares in AC Immune were up on Tuesday, after the firm announced encouraging results from a Phase II trial of its Alzheimer’s disease (AD) candidate. 31 August 2021
Chinese biopharma firm Innovent Biologics and US biotech Bolt Biotherapeutics have announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates. 31 August 2021
Japanese pharma major Eisai has concluded a license agreement concerning dotinurad, a treatment for hyperuricemia and gout discovered by Fuji Yakuhin, for development and distribution in five ASEAN (Association of Southeast Asian Nations) member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand. 31 August 2021
Russia again faces a shortage of foreign drugs for the treatment of serious diseases, this time for the treatment arthritis, according to recent statements by representatives of local patent associations and some local media, reports The Pharma Letter’s local correspondent. 31 August 2021
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Evrenzo (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD). 31 August 2021
Daiichi Sankyo has concluded an agreement on commercialization collaboration in Japan with the local subsidiary of US pharma major Eli Lilly for the 5-HT1F receptor agonist lasmiditan succinate, for which Eli Lilly Japan has submitted a new drug application for the treatment of migraines. 31 August 2021
These are billed as being exciting times for cell and gene therapies, but seasoned observers of the pharmaceutical industry would be forgiven for taking that billing with a pinch of salt. 31 August 2021
A raft of measures adopted by the US government to enhance the availability of drugs are impacting the margins of Indian companies. While several Indian drugmakers have witnessed a decline in their US generic business on a quarter-on-quarter (QoQ) and year-on-year (YoY) basis, few companies have taken inventory write-offs and also tried to liquidate the high inventory carried by them in the US market, reports The Pharma Letter’s India correspondent. 31 August 2021
A huge patent opportunity is supporting the Indian pharmaceutical sector, as several older and once lucrative drugs are losing their patent, presenting a $240 billion opportunity over the next five-six years until 2026. 31 August 2021
The protection of intellectual property (IP) rights currently remains one of the most pressing problems for global drugmakers operating in the Russian market, according to recent statements by Oksana Monzh, general director of French pharma major Sanofi in the Eurasian Region and representatives of other producers. 31 August 2021
Revelation Biosciences, a clinical-stage life sciences company focused on the development of immunologic based therapies for the prevention and treatment of disease, and Petra Acquisition, a special purpose acquisition company (SPAC), have entered into a definitive merger agreement for a business combination that will result in Revelation Biosciences becoming a publicly traded company. 30 August 2021
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in the USA, the first generic to its reference medicine to be approved by the US Food and Drug Administration (FDA). 11 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pfizer is to present initial findings from its CULTIVATE study of its sphingosine-1-phosphate (S1P) receptor modulator Velsipity (etrasimod) in Crohn’s disease (CD) at United European Gastroenterology Week 2024. 11 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Switzerland-based KeyBioscience and US pharma major Eli Lilly have agreed to extend their collaboration on the development of dual amylin calcitonin receptor agonists (DACRA), a new class of potential treatments for obesity and related disorders. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of the Quarterly Biosimilar Market Report in the United States. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024